特发性炎性肌病患者重组带状疱疹疫苗的免疫原性、安全性与应答决定因素
本分析基于一项随机双盲安慰剂对照研究,纳入70例接受免疫抑制治疗的特发性炎性肌病(IIM)患者与280名健康对照,均接种两剂重组带状疱疹疫苗(RZV)。IIM组血清转化率低于对照(83.3% vs 99.3%),接种后抗体几何平均滴度(GMT)与增幅均较低;霉酚酸酯使用、基线皮肤活动度高和基线GMT高与血清转化降低独立相关。疫苗总体安全,未观察到疾病活动度增加。
要点
- IIM患者RZV血清转化率为83.3%,低于健康对照的99.3%。
- 霉酚酸酯使用与基线皮肤活动度高与血清转化降低独立相关。
- 疫苗与安慰剂组疾病活动评分无差异,安全性可接受。
核心结论
- RZV在多数接受免疫抑制治疗的IIM患者中安全并诱导血清转化,无疫苗相关疾病活动证据,但抗体应答减弱。
研究设计与样本
- 一项随机双盲安慰剂对照研究的亚组分析,纳入70例符合2017 ACR/EULAR标准的免疫抑制成人IIM患者和280名健康对照,均接种两剂RZV。
主要发现
- IIM组血清转化率83.3%低于对照99.3%(P<0.001),接种后GMT为6.4 vs 11.8 mIU/mL(P=0.001),FI-GMT为21.8 vs 53.0(P=0.001)。
- IIM组不良事件报告率50.0%(35/70)低于对照72.8%(204/280)(P<0.001),多为轻度。
- 疫苗与安慰剂组间疾病活动评分无差异(P>0.05)。
关键数值与推荐
- 血清转化定义为抗gE抗体≥4倍升高;霉酚酸酯使用、基线皮肤活动度较高和基线GMT较高与血清转化降低独立相关(P<0.05)。
临床怎么用
- 对接受霉酚酸酯或皮肤活动度高的IIM患者,可考虑个体化接种策略以优化保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the immunogenicity and safety of the recombinant zoster vaccine (RZV) in immunosuppressed patients with idiopathic inflammatory myopathies (IIM), with particular focus on its impact on disease activity. METHODS: This subanalysis of a randomized, double-blind, placebo-controlled study included 70 immunocompromised adult patients with IIM (2017 ACR/EULAR criteria) and 280 healthy controls (control group [CG]), who received two RZV doses. Seroconversion was defined as a ≥4-fold increase in anti-gE antibodies. Geometric mean titers (GMT) and factor increase (FI) were assessed, and multivariable regression analyses were performed to identify factors associated with seroconversion. Patients were randomized 1:1 to receive RZV or placebo during the blinded phase, and disease activity was evaluated using validated instruments (visual analog scale, the Myositis Disease Activity Assessment Visual Analog Scale, Manual Muscle Test-8 (MMT-8), Health Assessment Questionnaire, and the modified Medical Research Council dyspnea scale and serum muscle enzymes. RESULTS: Patients with IIM were younger (53 vs 55 years, P = 0.005) and had a higher prevalence of previous herpes zoster (36.7% vs 13.3%, P < 0.001) than CG. Seroconversion rates were lower in IIM compared with CG (83.3% vs 99.3%, P < 0.001), with reduced post-vaccination GMT (6.4 vs 11.8 mIU/mL, P = 0.001) and FI-GMT (21.8 vs 53.0, P = 0.001). Mycophenolate mofetil use, higher baseline cutaneous activity, and higher baseline GMT were independently associated with reduced seroconversion (P < 0.05). Adverse events, mostly mild, were reported by 35 of 70 (50.0%) patients with IIM and by 204 of 280 (72.8%) CG (P < 0.001). No differences in activity scores were observed between vaccine and placebo groups (P > 0.05). CONCLUSION: RZV was safe and induced seroconversion in most immunosuppressed patients with IIM, without evidence of vaccine-related disease activation. Attenuated antibody responses, particularly in patients receiving mycophenolate mofetil or with active cutaneous disease, support individualized vaccination strategies to optimize protection in this high-risk population (ClinicalTrials.gov NCT05879419).
引用
- Pasoto SG, Gorayeb THB, Luppino-Assad AP, et al. Immunogenicity, Safety, and Determinants of Recombinant Zoster Vaccine Response in Idiopathic Inflammatory Myopathies: A Phase 4 Randomized Trial. Arthritis Care Res (Hoboken). 2026. PMID: 42294825. doi:10.1002/acr.80103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。